Core Viewpoint - Bank of America Securities reports that WuXi Biologics has issued a positive earnings forecast, expecting a 16.7% year-on-year revenue growth to reach 21.8 billion yuan by 2025, aligning with the bank's expectations [1] Revenue and Growth - The revenue growth is attributed to a record number of new projects and an expansion of service offerings, particularly in the BsAb and ADC platforms [1] - The revenue forecast for 2025 to 2027 has been slightly increased by 1% [1] Profitability - Gross margin is expected to expand by 5 percentage points year-on-year to 46%, surpassing the bank's expectations due to improved capacity utilization and efficiency gains from the Lean Operations Management System (WBS) [1] - Net profit and net profit attributable to shareholders are projected to be 5.7 billion yuan and 4.9 billion yuan, respectively, reflecting year-on-year growth of 45.3% and 46.3% [1] - Net profit forecast has been raised by 7% [1] Target Price and Rating - The target price has been adjusted from 41.8 HKD to 47 HKD, while maintaining a "Neutral" rating [1]

产品研发进展 四价流感病毒裂解疫苗(儿童)项目：III期临床试验受试者已全部完成入组，并完成疫苗接种，目前血清 正在中国食品药品检定研究院检验，等待后续结果。 三价流感病毒裂解疫苗：上市生产申请已获受理，并完成注册检验、标准复核等程序，目前等待国家药 品监督管理局药品审评中心的进一步审评结果。这些审评进展可能影响公司未来产品线拓展。 财务状况 经济观察网金迪克(688670)近期公告显示，公司2025年业绩预亏，主要因研发投入增加及计提资产减值 准备和存货报废处置。同时，其疫苗研发项目取得阶段性进展。 业绩经营情况 公司已于2026年1月30日发布业绩预告，预计2025年归属于上市公司股东的净利润亏损1.6亿元至1.8亿 元，同比增亏。主要原因是研发投入增加及计提资产减值准备和存货报废处置约4,199.96万元。投资者 可关注后续年度报告的正式披露，以获取经审计的财务细节。 公司2025年度计提资产减值准备及部分存货报废处置合计约4,199.96万元，该事项已影响当期利润，投 资者可关注年度报告中对此的详细说明及潜在财务调整。 此外，公司曾于2026年1月26日因股价波动登上龙虎榜，但此类事件属短期市场行为。 ...

Group 1 - The core viewpoint of the article is that Watson Bio (300142) is currently in the Phase III clinical research stage for its nine-valent HPV vaccine [1] - The company stated that updates regarding the vaccine's development progress should be based on announcements disclosed by the company [1]

Core Insights - The letter from Ganli Pharmaceutical reflects on the challenges and achievements of 2025, emphasizing the importance of resilience and commitment to quality in the pharmaceutical industry [4][5] - The company projects a net profit of 1.1 billion to 1.2 billion yuan for 2025, representing a year-on-year growth of 78.96% to 95.23%, driven by domestic market recovery and international revenue growth [4][5] - Ganli Pharmaceutical is committed to internationalization, with significant milestones achieved in various global markets, including the approval of its insulin product in Ethiopia and a partnership in Brazil [5][6] Financial Performance - The expected net profit for 2025 is between 1.1 billion and 1.2 billion yuan, marking a substantial increase compared to the previous year [4] - The growth is attributed to the recovery of the domestic market, structural optimization, and sustained international revenue [4] Internationalization Efforts - Ganli Pharmaceutical has made significant strides in international markets, with a systematic approach to registration and collaboration [5][6] - The company has entered the Sub-Saharan African market with its insulin product and has established a long-term supply agreement in Brazil worth no less than 3 billion yuan [5] - The approval of Ondibta® in the EU marks a milestone as the first Chinese third-generation insulin to enter the European market, showcasing the company's alignment with international standards [6] Research and Development - The company continues to invest in R&D, focusing on metabolic diseases with several innovative pipelines advancing to critical clinical stages [6][7] - Ongoing projects include GLP-1 receptor agonists and long-acting insulin formulations, with research findings being published in international academic forums [6][7] Future Outlook - Ganli Pharmaceutical aims to maintain a steady pace in its internationalization strategy while enhancing its R&D capabilities to meet global market demands [7] - The company is committed to contributing to the global biopharmaceutical industry and providing reliable treatment options for patients [7]

股票近期走势 尽管有上述进展，艾美疫苗(06660.HK)的股价近期出现回调。截至2026年2月12日，股价报收3.03港 元，单日下跌5.90%，近20个交易日累计下跌18.98%。股价波动可能受以下因素影响：整体市场环境： 近期港股市场整体表现震荡，恒生指数同期有所下跌，医药板块也面临一定压力。短期业绩承压：公司 2025年上半年收入为5.15亿元人民币，同比小幅下降4.2%，主要原因是其核心产品狂犬疫苗收入有所下 滑。尽管亏损同比收窄，但短期业绩波动可能影响市场情绪。研发投入与商业化进程：虽然研发费用同 比有所下降，但创新药企在重磅产品获批上市前，仍需持续投入，其业绩贡献存在一定的时间滞后性。 市场可能在等待产品正式商业化并产生收入贡献的更明确信号。 以上内容基于公开资料整理，不构成投资建议。 经济观察网艾美疫苗近期在研管线取得显著进展，但其股价表现受到市场环境、短期业绩及商业化进程 等多重因素影响。 公司项目推进 公司在研管线取得显著进展。其全球首研的无血清迭代狂犬疫苗已于2026年2月5日公告顺利通过国家药 监局的注册现场检查，标志着该产品距离正式上市更近一步。此外，公司的13价肺炎结合疫苗 (PC ...

Core Viewpoint - Nomura's report indicates that WuXi Biologics has announced a profit forecast, expecting a 16.7% year-on-year revenue growth to 21.8 billion yuan in 2025, slightly above the market expectation of 21.5 billion yuan [1] Revenue and Profit Forecast - The gross margin is expected to improve by 5 percentage points year-on-year to 46%, also exceeding the market expectation of 43% [1] - Net profit and profit attributable to shareholders are projected to grow by 45.3% and 46.3% year-on-year, reaching 5.7 billion yuan and 4.9 billion yuan, respectively, surpassing market expectations of 4.8 billion yuan and 4.4 billion yuan [1] - For the second half of 2025, revenue is estimated to grow by 17.2% year-on-year to 11.8 billion yuan, with profit growth of 38%, both exceeding market expectations [1] Management Insights - Management attributes the growth to optimistic performance in research service revenue and an increase in projects entering later stages due to enhanced service capabilities [1] Target Price Adjustment - Nomura has raised its target price from 37.36 HKD to 50.54 HKD, maintaining a "Buy" rating [1]

21世纪经济报道记者唐唯珂报道 深耕胰岛素领域十年后，华润系选择与天麦生物"分道扬镳"。 2月9日，华润医药发布公告称，其全资附属公司华润医药投资拟通过上海联合产权交易所公开挂牌，转 让所持合肥天麦生物科技发展有限公司(下称"天麦生物")约17.87%股权，挂牌底价约14.2亿元。以此计 算，该笔股权对应天麦生物整体估值约80亿元。 据华润医药集团公告，若确定意向受让方，双方将订立相关协议；若期满未果，则本次公开挂牌将自动 失效并终止。根据上海联合产权交易所网站，信息披露日期截止到3月13日。这意味着，留给潜在意向 方的时间已经不多了。 尽管此次华润医药投资并未清仓所有股份，但华润系退意已决。目前，华润医药投资作为天麦生物第一 大股东，手握20%股权。一旦这笔交易落槌，其持股将降至5.88%，彻底告别大股东之位，其附属公司 (持有3.75%股权)将彻底退出。 华南某券商从业者向21世纪经济报道记者指出，从2016年战略入股携手开拓胰岛素市场，到2026年挂牌 出让大部分股权，这场持续十年的合作落幕，既折射出华润系聚焦主业的资产整合逻辑，也与天麦生物 核心研发管线口服胰岛素遇挫、行业竞争格局变化密切相关。 口服 ...

Company Project Advancement - The company is actively promoting the market launch and sales of calcium silicate bio-ceramic oral bone repair materials, planning to adopt a differentiated marketing strategy based on product innovation advantages [1] - The meningeal series products have won bids in 24 provinces for volume procurement projects, with the Beijing-Tianjin-Hebei "3+N" alliance procurement project set to start in December 2025, and the company is progressing with related preparations as planned [1] Product Development Progress - The uterine cavity repair membrane is set to enter the registration phase in early January 2026, having received the registration acceptance notice [2] - The breast patch is expected to complete clinical trial summaries by November 2025, and preparations for registration are currently underway [2] Company Business Status - In 2026, the company plans to accelerate the market promotion and terminal volume of active biological bone to enhance revenue contribution [3] - Several products have export potential, and the company is evaluating market access requirements and feasibility in different countries and regions, conducting preliminary preparation work [3]

Core Viewpoint - The company has terminated its vaccine joint venture project with AstraZeneca due to significant market changes and increased industry pressures, leading to a projected decline in 2025 earnings by over 60% [2][4]. Recent Events - The company announced on February 6, 2026, the termination of the vaccine joint venture project with AstraZeneca, which was initially planned with an investment of approximately 2.76 billion yuan. The project had not received actual funding since its signing in March 2025 [2]. - This decision may impact the company's external expansion efforts, but the company intends to focus on internal innovation [2]. Company Status - Shareholder Yuan Liping has terminated the concerted action relationship with the actual controller Du Weimin and plans to transfer up to 22.33 million shares (2.00% of total share capital) through block trading. This change does not involve market reduction but may raise concerns about governance structure [3]. Performance and Operating Conditions - According to the earnings forecast released on January 29, 2026, the company expects a net profit attributable to shareholders of 49 million to 73 million yuan for 2025, representing a year-on-year decline of 63.8% to 75.7%. This decline is primarily due to adjustments in the immunization schedule for the quadrivalent vaccine, increased operating costs, and higher R&D investments [4]. - During the same period, overseas business revenue reached 98.84 million yuan, a significant increase of 859.40% [4]. Business and Technical Development - In 2025, the company initiated Phase III clinical trials for a domestically produced pentavalent vaccine and received approval for a 60 microgram hepatitis B vaccine aimed at "preventing reactivation," marking an extension into the therapeutic vaccine field [5]. - R&D investment was approximately 633 million yuan, reflecting a year-on-year growth of 11.25%. The company is also leveraging AI technology to enhance R&D and has expanded its global presence to over 20 countries [5]. Executive Changes - Vice President Yu Bing resigned in early February 2026 but will continue to hold other positions within the company. Market speculation suggests this may be related to performance pressures, although the company states it will not affect normal operations [6].

兴齐眼药（300573.SZ）2月12日在投资者互动平台表示，截至目前，公司持有泰州兴普泰生物制药有限 公司3.33%的股权。公司对兴普泰的股权投资属于围绕产业链上下游的战略性投资。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：今年国产口服司美格鲁肽将会大批量陆续上市，公司 参股公司泰州兴普泰生物制药有限公司今年业绩是否会迎来爆发式增长？ ...